Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


India’s Matrix To Hold Controlling Interest In Astrix Joint Venture

This article was originally published in PharmAsia News

Executive Summary

U.S.-based Mylan Laboratories and its Indian arm, Matrix Laboratories, have agreed that Mylan will buy a half interest in Astrix Laboratories, a joint venture that makes anti-retroviral active pharmaceutical ingredients. Matrix and Aspen Pharmacare Holdings of South Africa formed Astrix as a joint venture, but decided last year that Matrix would buy out Aspen's 50 percent share. Instead, the plan now is to have Mylan, Matrix's parent, buy 49 percent of Aspen's shares through another Mylan subsidiary and Matrix's immediate parent, MP Laboratories of Mauritius. Matrix, already a 50 percent owner, is to buy the remaining 1 percent for control of Astrix. (Click here for more

You may also be interested in...

Catchup Capsule: Key APAC Insights You Need To Read

Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.

QUOTED. 4 December. Eric Borin.

Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.

Pfizer’s Expected 2020 COVID-19 Vaccine Production Fell By 50% After Scaleup Delays

Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts